MedTrace Logo

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

NCT02022917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-01-27

No results posted yet for this study

Summary

This study is to determine the feasibility of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC or IV ovarian, tubal, and peritoneal cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Bevacizumab

Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Asian Gynecologic Oncology Group

    collaborator OTHER

  • Taiwanese Gynecolgic Oncology Group

    collaborator UNKNOWN

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chyong-Huey Lai, MD · Chang Gung Memorial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022917 on ClinicalTrials.gov